# Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer

> **NCT02214602** · PHASE4 · COMPLETED · sponsor: **Mansoura University** · enrollment: 240 (actual)

## Conditions studied

- Carcinoma of Urinary Bladder, Superficial

## Interventions

- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT02214602
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2017-04
- **Final completion:** 2017-05
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2018-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214602, "Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02214602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*